The Center for Immuno-Oncology (CIO) investigates how our immune system reacts to cancer and what we can do to improve tumour immunity. We combine deep fundmental understanding of immunology with preclinical studies to translate new knowledge into clinical trials with the aim of developing new life-saving treatments for a spectrum of cancers.
Oxford’s long history of excellence in immunology is now focused on cancer, and CIO is the hub of the University-wide Oxford Cancer Immuno-Oncology Network (OCION) which links immuno-oncology researchers from multiple disciplines from across the University of Oxford, its affiliated hospitals and industrial partners.
What's new for Oxford Cancer
-
Kezia Gaitskell awarded a UKRI Future Leaders Fellowship
16 September 2025
-
Iron Levels Found to Play a Key Role in FLASH Radiotherapy’s Tissue-Sparing Effect
16 September 2025
-
New Study Evaluates Effectiveness of Cancer Diagnosis Pathway for Patients with Non-Specific Symptoms
10 September 2025
-
Join our Healthy Volunteer Blood Donation Campaign!
8 September 2025
-
The Kaiya Foundation to fund leukaemia research at University of Oxford
2 September 2025
CIO News
A Day of Science, Creativity, and Connection at the CIO Away Day
6 August 2025
The Centre for Immuno-Oncology came together last week for a vibrant and inspiring CIO Away Day. In the beautiful Rhodes house we enjoyed a full day of science, creativity, reflection, and community.
Professor Andrew McMichael elected to the US National Academy of Sciences
20 May 2025
The National Academy of Sciences (NAS) in the US announced the election of 120 members and 30 international members in recognition of their distinguished and continuing achievements in original research. Election to membership in the NAS is a mark of excellence in science and is considered one of the highest honours that a scientist can receive.
Oxford Immunology Symposium 2025
3 February 2025
The BSI Oxford Immunology Group, in collaboration with the University of Oxford Immunology Network, is pleased to present a one-day showcase of the fantastic immunology research happening across Oxford.
Agonists and Antagonists in Combined Immunotherapies for Cancer
3 February 2025
Prof. Nacho Melero delivers a talk on Immunotherapies in Cancer for GLOBAL IMMUNOTALKS
Latest publications
-
Targeting MHC-E as a new strategy for vaccines and immunotherapeutics
Journal article
Frueh K. et al, (2025), Nature Reviews Immunology
-
Nanotechnology for immuno-oncology.
Journal article
Grippin AJ. et al, (2025), Nature cancer
-
Adsorption of antigen to polymeric nanoparticles enhances cytotoxic T-cell responses and anti-tumor immunity by targeting conventional type 1 dendritic cells.
Journal article
Huete-Carrasco J. et al, (2025), Immunology and cell biology
-
T cell engagers: expanding horizons in oncology and beyond.
Journal article
Albayrak G. et al, (2025), Br J Cancer
-
Atom-level mechanism of tapasin-independent peptide editing by Major Histocompatibility Complex class I molecules
Preprint
Turner S. et al, (2025)
-
Strict advantage of complex quantum theory in a communication task
Journal article
Elliott TJ., (2025), Physical Review A, 111
-
Antigen-presenting mast cells are new players in breast cancer immunotherapy.
Journal article
Luri-Rey C. et al, (2025), Nature medicine
-
In vivo labelling resolves distinct temporal, spatial, and functional properties of tumour macrophages, and identifies subset-specific effects of PD-L1 blockade.
Journal article
Lee CY. et al, (2025), Cancer immunology research
-
Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer.
Journal article
Ruiz-Fernández de Córdoba B. et al, (2025), Signal transduction and targeted therapy, 10
-
Phase II study of perioperative Avelumab plus chemotherapy for patients with resectable gastric cancer or gastroesophageal junction cancer - the MONEO Study.
Journal article
Alsina M. et al, (2025), Clin Cancer Res
-
Supplemental Figure 2 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplementary Figure S1 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplemental Figure 5 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplemental Figure 3 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplemental Figure 4 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
Oxford Talks
-
Wednesday, 17 September 2025, 9.30am to 11am
Speakers: Dr Joanna Anderson
Venue: 15 Norham Gardens, 15 Norham Gardens OX2 6PY
-
Wednesday, 17 September 2025, 12pm to 1pm
Speakers: Mr Matthew Gardiner, Mr Ryan Kerstein
-
Wednesday, 17 September 2025, 1pm to 2pm
Speakers: Professor Hernando Ombao
Venue: Big Data Institute, Old Road Campus OX3 7LF
-
Thursday, 18 September 2025, 10am to 10.30am
Speakers: Ethan Booth
Venue: Wellcome Trust Centre for Human Genetics, Headington OX3 7BN
-
Thursday, 18 September 2025, 11am to 12pm
Speakers: Prof Maddy Parsons
Venue: NDM Building, Headington OX3 7FZ